JP Morgan Maintains Overweight on Denali Therapeutics, Lowers Price Target to $24

Benzinga · 01/07 19:10
JP Morgan analyst Jessica Fye maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $28 to $24.